Investing

Cardiex September 2024 Quarter Update

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.

Highlights:

Manufacturing of the initial 8,000 CONNEQT Pulse units commenced with the expected arrival of units in the USA late-November/early December.
Pulse waitlist now exceeds 20,000 with activities now focused on sales conversion.
Completed clinical validation study of wearable technology, with an FDA pre-submission meeting scheduled for November to advance the clearance process.
Completion of usability study for submission for additional OTC clearance for the Pulse.
Strong clinical sales pipeline with momentum towards new Q2 contracts.
Grand prize winner of the U.S. National Institute of Health’s RADx® Maternal Health Challenge securing US$525,000 in prize funding.
New R&D Term Loan Facility with Mitchell Asset Management to provide additional flexibility with R&D initiatives and working capital requirements.

Click here for the September Quarterly Appendix 4C

Click here for the full ASX Release

This post appeared first on investingnews.com

You May Also Like

Investing

Overview Rua Gold (CSE:RUA,OTC:NZAUF,WKN:A4010V,OTCQB:NZAUF) is a gold exploration company focused on two prolific, historic gold-producing regions in New Zealand: Hauraki Goldfield and Reefton Goldfield....

Editor's Pick

Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

Stock

Warner Bros. Discovery said Thursday its streaming platform Max added 7.2 million global subscribers in the third quarter. It marked the biggest quarterly growth for...

Economy

The Israel Defense Forces (IDF) announced the death of Fuad Shukr, the Hezbollah commander who was behind a drone strike that killed 12 children...

Disclaimer: wisetradeinvesting.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 wisetradeinvesting.com